Solarbiotech is a U.S.-based synthetic biology and biomanufacturing company that helps companies move precision-fermentation products from lab bench to commercial scale. Built around a Norton, Virginia plant with fermentation capacity from 6L to 10,000L and a modular 'BioNodes' architecture, it offers end-to-end strain-to-shelf services - upstream fermentation, downstream processing, and commercial production - for food ingredients, nutraceuticals, cosmetics, enzymes, and industrial bioproducts. After a 2024 Chapter 11 restructuring, its assets were acquired by Pictor Biotech (led by ex-Novozymes executive Peter Rosholm) and unified in January 2025 with GPC Bio and Eleszto Genetika into a vertically integrated, 100+ person SynBio platform.

Eric Abbate is a synthetic-biology scientist turned CEO who led Solar Biotech, a Virginia-based startup building solar-powered, water-neutral fermentation plants to make biodesigned cosmetics, food ingredients and bioelectronic components. A UC Berkeley-trained molecular and cell biologist, he ran high-throughput genome-engineering and analytical biochemistry teams at Inscripta and was corresponding author on a widely cited paper on optimizing strain engineering for industrial-scale production. He steered Solar Biotech from lab science toward a modular 'BioNodes' manufacturing model before the company entered Chapter 11 in 2024 with plans to sell its assets and reboot.